Bio Medica Laboratories IPO

The company manufactures:

• Liquid injections

• Dry powder injections

• Single-dose injectables

• Multi-dose injectables

Its manufacturing facilities are located in the Sanwer Road Industrial Area, Indore, Madhya Pradesh.

Unlike branded pharma companies that directly target consumers, Bio Medica follows a B2B contract manufacturing model. It manufactures pharmaceutical products for third-party marketers and pharma companies that sell products under their own brands.

The IPO consists of:

India’s pharmaceutical industry remains one of the fastest-growing healthcare sectors globally. The country is already among the world’s largest suppliers of generic medicines and vaccine manufacturing.

The injectable formulations market is witnessing strong growth because of:

• Rising hospitalization rates

• Growth in critical care treatment

• Expansion of veterinary healthcare

• Increasing demand for sterile formulations

• Government healthcare spending

• Export opportunities for generic medicines

India’s pharma market is expected to maintain high single-digit to low double-digit CAGR growth over the next few years, supported by:

• Ayushman Bharat

• Production Linked Incentive (PLI) schemes

• Expansion of healthcare infrastructure

• Rising chronic disease burden

Injectable manufacturing is considered a specialized segment because sterile production requires strict regulatory compliance, controlled environments, and advanced quality testing systems. This creates relatively higher entry barriers compared to oral dosage manufacturing.

Bio Medica operates in this niche injectable segment, which can offer better margins and long-term institutional demand if quality standards are maintained consistently.

Bio Medica manufactures pharmaceutical parenteral formulations primarily through contract manufacturing arrangements.

The company’s business model works like this:

1. Pharma marketers outsource manufacturing

2. Bio Medica manufactures formulations as per specifications

3. Products are packed under client branding

4. Clients market the finished products

This asset-backed B2B structure helps the company generate repeat manufacturing orders without spending heavily on direct consumer marketing.

Product Portfolio

The company manufactures:

Human Injectables

• Antibiotic injections

• General therapeutic injectables

• Dry powder formulations

• Liquid formulations

Veterinary Injectables

• Animal healthcare injectables

• Multi-dose veterinary products

The company’s manufacturing capabilities include both single-dose and multi-dose packaging formats.

Manufacturing Infrastructure

Bio Medica operates manufacturing units in Indore’s industrial belt.

Unit Details

One important disclosure is that operations at Manufacturing Unit-I were suspended in August 2023 following regulatory observations by the Food and Drug Administration, Madhya Pradesh.

This remains one of the most critical operational risks for investors.

Quality Certifications and Compliance

The company has obtained:

• GMP Certification

• GLP Certification

issued by the Food & Drugs Administration, Madhya Pradesh.

Its laboratory infrastructure includes:

• HPLC systems

• Gas chromatography

• UV spectrophotometers

• Polarimeters

• Advanced analytical instruments

These systems are essential for maintaining injectable quality standards and batch validation processes.

Pharmaceutical manufacturing is one of the most tightly regulated sectors in India.

Bio Medica operates under multiple laws and regulatory frameworks, including:

The company also maintains registrations related to:

• GST

• EPFO

• ESIC

• Shops & Establishment licenses

• PAN and TAN registrations

One notable disclosure is that certain approvals still carry the old private limited company name and are being updated after conversion into a public company.

Every SME IPO carries business and operational risks, but Bio Medica has a few particularly important ones investors should understand carefully.

1. Manufacturing Unit Suspension Risk

The biggest risk is linked to the suspension of operations at Unit-I after regulatory inspections conducted jointly by CDSCO and state authorities.

This indicates that the company operates in a highly compliance-sensitive business where any deviation can immediately affect production.

2. High Debt Levels

The company previously operated with relatively elevated leverage.

Management plans to use part of IPO proceeds for repayment of borrowings, which may reduce finance costs going forward.

3. Leased Property Dependence

The company does not own its primary operating facilities. Manufacturing units and offices operate on leased industrial land arrangements from the Government of Madhya Pradesh.

Any disruption in lease continuity could affect operations.

4. Related Business Conflict Risk

Promoter-linked entities such as:

• Italia Pharmaceuticals Private Limited

• Bio Medica Parentals

operate in similar pharmaceutical businesses.

Although non-compete agreements are in place, overlapping business interests remain a monitorable factor.

The company is promoted by:

• Pradeep Mehta

• Mukesh Mehta

Both are founding members associated with the company since incorporation.

Pradeep Mehta

He oversees:

• Strategy

• Innovation

• Operations

• Business growth

Mukesh Mehta

Mukesh Mehta serves as Whole-Time Director and manages:

• Sales

• Marketing

• Business development

• Operational expansion

He also carries over 18 years of pharmaceutical industry experience.

The promoter group includes multiple pharma-linked businesses.

Group Companies

Sears Phytochem Private Limited

Engaged in:

• Chemicals

• Drug intermediates

• Pharmaceuticals

• Healthcare products

Italia Pharmaceuticals Private Limited

Focused on:

• Pharmaceutical manufacturing

• Drug formulations

• Cosmetic and medicinal products

Other Group Entity

Bio Medica Parentals

A partnership firm involved in pharmaceutical manufacturing.

The presence of related pharma businesses creates both operational synergies and potential conflict-of-interest concerns.

The company has built a management structure around pharmaceutical manufacturing, production, compliance, and legal operations.

Key Personnel

Pradeep Mehta – Managing Director

Leads:

• Business strategy

• Operations

• Expansion planning

Mukesh Mehta – Whole-Time Director

Handles:

• Sales

• Marketing

• Business development

Garima Mehta – Legal Manager

Responsible for:

• Regulatory compliance

• Legal matters

• Governance oversight

Mamta V. Bhatnagar – Production Manager

One of the most experienced professionals in the organization.

Highlights:

• PhD in Organic Chemistry

• 32+ years pharma manufacturing experience

• Expertise in injectables and ophthalmic formulations

The company has constituted standard governance committees required for listed entities, including:

• Audit Committee

• Nomination & Remuneration Committee

• Stakeholders Relationship Committee

The board includes independent directors with legal and secretarial backgrounds.

Independent Directors

Divya Khandelwal

• Company Secretary

• Legal professional

• Expertise in compliance and governance

Sumeet Bansal

• Company Secretary

• Law graduate

• Experience in secretarial and legal matters

The governance structure appears aligned with SME listing requirements, although investors may continue monitoring governance maturity post listing

For a pharmaceutical manufacturer, regulatory discipline is extremely important because even small compliance gaps can affect production continuity.

Bio Medica currently does not have any outstanding criminal or civil litigation against the company.

However, the company has disclosed a significant regulatory matter involving one of its manufacturing units.

FDA Suspension Order on Manufacturing Unit-I

A major action was initiated by the Office of the Controller, Food and Drugs Administration, Madhya Pradesh against the company’s Unit-I facility located at Sector-F, Sanwer Road, Indore.

Key Details

The inspection was conducted jointly by:

• CDSCO Headquarters

• State FDA officials

• CDSCO Sub-Zone Indore

The inspection took place between June 7 and June 9, 2023.

As a result, production at Unit-I was suspended under Rule 85(2) of the Drugs and Cosmetics Rules, 1945.

For investors, this is not a minor disclosure. Regulatory interruptions in injectable manufacturing can impact:

• client confidence

• future contracts

• capacity utilization

• compliance reputation

The company continues to operate Unit-II.

Bio Medica has obtained several statutory registrations and operational licenses necessary for pharmaceutical manufacturing.

Corporate Registrations

Tax Registrations

The company holds:

• PAN

• TAN

• GST Registration

• Professional Tax Registration

Labour and Employee Registrations

Operational Certifications

The company has:

• GMP certification

• GLP certification

These approvals are especially critical in sterile injectable manufacturing because quality compliance directly affects production permissions.

The company has also clarified that there are no major pending approvals currently awaiting grant from government authorities.

Bio Medica’s financial performance reflects a rapidly scaling SME pharmaceutical manufacturing business.

The company has shown strong profitability growth in FY25, supported by better operational performance and higher manufacturing scale.

Financial Snapshot

*FY25 NAV adjusted post bonus issue.

The sharp change in NAV reflects restructuring and bonus adjustments before the IPO.

Revenue and Profitability Analysis

The company’s business appears to have scaled aggressively over recent periods due to:

• higher injectable demand

• contract manufacturing growth

• increased production volumes

One positive sign is the strong profitability profile reflected in:

• high return on net worth

• improving leverage

• healthy earnings growth

However, investors should also note that SME pharma businesses can experience:

• volatile working capital cycles

• customer concentration

• fluctuating raw material costs

• regulatory disruptions

Margin Movement

Injectable manufacturing generally offers stronger margins than commodity oral formulations because:

• sterile manufacturing has higher entry barriers

• quality standards are stricter

• fewer players operate at scale

If Bio Medica successfully stabilizes compliance and expands manufacturing utilization, operating leverage may improve further.

The company has meaningful debt exposure across:

• LAP loans

• overdraft facilities

• working capital limits

• cash credit lines

• vehicle loans

Major Borrowings

Total borrowings exceeded ₹2,600 lakh based on disclosed facilities.

Security Against Loans

Loans are secured through:

• current assets

• stock

• receivables

• equitable mortgage on industrial properties

Collateral includes:

• Plot No. 11-B

• Plot No. 11-C

• Sector-F industrial properties

Debt Position Analysis

The company’s debt-heavy structure previously pushed debt-equity above 2x in FY23 and FY24.

This indicates:

• dependence on external financing

• working capital intensity

• expansion-related borrowing

A portion of IPO proceeds is earmarked for debt repayment, which could:

• lower interest burden

• improve net margins

• strengthen balance sheet flexibility

Cash flow quality is extremely important in SME manufacturing businesses because profits alone do not indicate liquidity strength.

Bio Medica operates in a business that typically requires:

• inventory stocking

• raw material procurement

• receivable financing

• production cycle funding

This naturally creates working capital pressure.

Working Capital Characteristics

Key working capital drivers include:

• pharma raw materials

• packaging inventory

• credit sales to pharma marketers

• production lead time

Since the company follows a contract manufacturing model, customer payment cycles can significantly affect liquidity.

Operating Cash Flow Perspective

The company’s improving profitability is positive, but investors should continuously monitor:

• receivable days

• inventory turnover

• debt servicing capability

• interest coverage

SME pharma manufacturers often require continuous reinvestment into:

• machinery

• sterile infrastructure

• quality systems

• validation equipment

That can keep free cash flows under pressure despite strong earnings growth.

Return on Net Worth (RONW)

This is exceptionally high and indicates strong profitability relative to equity base.

However, investors should remember:

• SME financials can be volatile

• bonus adjustments distort ratios

• small equity bases can exaggerate returns

Net Asset Value (NAV)

The sharp reduction in FY25 NAV reflects capital restructuring and bonus adjustments.

Debt-to-Equity Ratio

The improvement suggests:

• stronger profitability

• balance sheet normalization

• preparation for IPO listing

The management strategy revolves around scaling injectable manufacturing capabilities while strengthening quality systems.

The company’s key growth pillars include:

1. Contract Manufacturing Expansion

Bio Medica intends to grow through:

• third-party pharma manufacturing

• B2B supply relationships

• contract formulation production

This model helps reduce:

• branding expenses

• distribution costs

• marketing overheads

2. Focus on Injectable Segment

Injectables remain a relatively specialized segment in Indian pharma manufacturing.

Advantages include:

• better margins

• repeat institutional demand

• higher entry barriers

• long-term hospital consumption trends

3. Quality and Compliance Strengthening

After the Unit-I suspension episode, regulatory compliance will likely become a major strategic priority.

Management is expected to focus on:

• GMP upgrades

• documentation systems

• quality assurance

• audit preparedness

• process standardization

4. Capacity Expansion

The company has disclosed plans related to manufacturing facility expansion.

If executed successfully, expansion may:

• improve scale efficiencies

• support larger order volumes

• increase customer acquisition capacity

5. Debt Reduction Strategy

Reducing leverage is another important objective.

Lower debt could improve:

• interest coverage

• profitability stability

• banking flexibility

• operational cash flows

The IPO proceeds are expected to be utilized for multiple business objectives including balance sheet strengthening and expansion initiatives.

Key Objectives

Debt Repayment

A significant portion of proceeds will go toward repayment or prepayment of borrowings.

This could:

• reduce finance costs

• improve leverage ratios

• enhance profitability

Manufacturing Expansion

Funds are also expected to support:

• facility expansion

• infrastructure upgrades

• operational scaling

General Corporate Purposes

Like most SME IPOs, a portion will also support:

• working capital

• operational flexibility

• strategic growth initiatives

For investors, the use of proceeds appears largely business-oriented rather than promoter-focused because the fresh issue component is substantially larger than the OFS component.

Bio Medica Laboratories is entering the SME market at a time when investor interest in pharmaceutical manufacturing businesses remains healthy, especially in niche formulations and injectable manufacturing.

The valuation approach for the IPO appears to be driven by:

• improving profitability

• high return ratios

• scalable injectable manufacturing

• pharma sector demand outlook

• SME growth positioning

Peer Comparison

The company has compared itself with:

Management has itself clarified that these peers are not perfectly comparable due to differences in scale and business mix.

Valuation Perspective

Some positive valuation factors include:

Strong Return Ratios

The company reported exceptionally high return on net worth in FY25.

Specialized Manufacturing Segment

Injectable manufacturing typically commands better market valuations compared to generic commodity pharma manufacturing.

Improving Leverage

Debt reduction through IPO proceeds may improve profitability further.

However, investors should also factor in:

• regulatory history

• SME liquidity risk

• customer concentration possibility

• dependence on contract manufacturing

• operational concentration in a single geography

The IPO will dilute promoter ownership while increasing public participation.

IPO Structure

Post-Issue Capital

The issue structure suggests promoters will continue retaining substantial control after listing.

Promoter Shareholding

Pradeep Mehta

• 44,44,725 equity shares

• 48.42% pre-issue holding

Mukesh Mehta

• 44,44,816 equity shares

Together, the promoter group holds dominant ownership in the company.

Offer for Sale (OFS)

Both promoters are partially diluting holdings through the OFS portion.

The OFS size remains relatively small compared to the fresh issue portion, which is generally viewed positively because most proceeds are expected to remain within the company.

The company has disclosed a dividend policy section, but investors should understand that SME pharmaceutical companies in growth mode usually prioritize:

• debt reduction

• working capital

• manufacturing expansion

• compliance investment

• capacity addition

over aggressive dividend payouts.

At this stage, Bio Medica appears more focused on:

• scaling operations

• improving infrastructure

• strengthening balance sheet efficiency

As a result, future dividend payouts may depend on:

• profitability consistency

• cash flow generation

• regulatory stability

• expansion requirements

Bio Medica has multiple promoter-linked entities operating in the pharmaceutical sector.

These include:

• Italia Pharmaceuticals Private Limited

• Bio Medica Parentals

• Sears Phytochem Private Limited

Nature of Related Party Transactions

Related party interactions may involve:

• business arrangements

• operational support

• pharmaceutical activities

• shared industry ecosystem

Because some group entities operate in overlapping business segments, investors should continue monitoring:

• arm’s length pricing

• transfer arrangements

• conflict management

• governance practices

Conflict Mitigation

The company has disclosed execution of non-compete arrangements with overlapping promoter entities.

This is intended to reduce:

• business overlap concerns

• client diversion risk

• competitive conflicts

The company has entered into multiple agreements related to the IPO and business operations.

Major Agreements Include

Market Maker Arrangement

The market maker for the issue is:

Prabhat Financial Services Limited

A total of:

• 1,89,000 equity shares

have been reserved for market making activities.

This is important because SME-listed shares generally require market-making support for liquidity.

The IPO follows the 100% Book Building Process under the SME platform framework.

Allocation Structure

Lot Size

SME IPOs generally require higher retail investment amounts compared to mainboard IPOs because of larger minimum lot sizes.

Equity shareholders receive standard rights available under Indian company law and listing regulations.

Key Rights Include

Voting Rights

Shareholders can vote on:

• resolutions

• appointments

• corporate actions

Dividend Rights:

Eligible shareholders may receive dividends if declared.

Rights Issue Participation:

Shareholders can participate in future rights offerings.

Bonus Shares:

Shareholders become eligible for bonus allotments if announced.

Corporate Governance Protection:

Listed entity disclosures improve transparency requirements after listing.

The company has disclosed several important confirmations for investors.

SEBI and RBI Compliance

The company has confirmed that:

• promoters are not wilful defaulters

• no SEBI market access prohibition exists

• no securities law violations are pending

NSE Approval

The company has received approval from NSE for using the exchange name in connection with the IPO and proposed SME listing.

Regulatory Positioning

The company has also confirmed:

• no major pending government approvals

• no material criminal proceedings

• no material civil litigation

except the disclosed regulatory action involving Unit-I.

Bio Medica Laboratories enters the SME market as a specialized injectable pharmaceutical manufacturer with:

Key Strengths

• niche injectable manufacturing focus

• improving profitability

• strong return ratios

• established B2B manufacturing model

• experienced promoter background

• GMP and GLP certified operations

Key Concerns

• regulatory suspension history

• dependence on leased facilities

• elevated historical debt

• promoter-linked overlapping businesses

• SME liquidity risks

The company’s future growth will largely depend on:

• regulatory compliance consistency

• successful debt reduction

• customer retention

• manufacturing scale-up

• operational discipline after listing

For investors looking at SME pharmaceutical opportunities, Bio Medica represents a higher-risk, potentially higher-growth manufacturing business operating in a specialized segment of the Indian pharma industry.